Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…Background<p>Hyper-IgM syndrome (HIGM) is a genetic immunodeficiency characterized by elevated to normal IgM levels and decreased IgG, IgA, and IgE. The overlapping clinical presentations of different gene mutations complicate diagnosis and management.…”

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Density differences between pre- and post-measurements for program completers (N = 160). by Anton Kurapov (11346019)

Main baseline characteristics of patients included in the study. by Jie Liu (15128)

Subjects:

(A) Monthly drug costs of patients in the ESAs group and Roxadustat group. by Jie Liu (15128)

Subjects:

Study data. by Jie Liu (15128)

Subjects:

Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

Subjects:

Morisky score for ESAs group and Roxadustat group. by Jie Liu (15128)

Subjects:

Patient flow diagram. by Jie Liu (15128)

Subjects:

Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. by Jie Liu (15128)

Subjects:

Approval by the research ethics committee. by Jie Liu (15128)

Subjects:

(A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups. by Jie Liu (15128)

Subjects:

S1 Data - by Bowen Deng (3123237)

“…We identified 4 longitudinal trajectories of blood glucose, including class 1 (a low initial average blood glucose level with steady trend within 24 hours), class 2 (a high initial average blood glucose with gently decreased trend), class 3 (the highest initial average blood glucose with rapidly decreased trend) and class 4 (a high initial average blood glucose level with the trend that increased at first and then decreased). …”

Characteristics of AMI patients with DM. by Bowen Deng (3123237)

“…We identified 4 longitudinal trajectories of blood glucose, including class 1 (a low initial average blood glucose level with steady trend within 24 hours), class 2 (a high initial average blood glucose with gently decreased trend), class 3 (the highest initial average blood glucose with rapidly decreased trend) and class 4 (a high initial average blood glucose level with the trend that increased at first and then decreased). …”

Survival function analysis of mortality for Viral load status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Multivariate Cox proportional hazard analysis ratio of patient factors associated with treatment outcomes in HIV care, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Schematic presentation of sampling of population for analysis. by Ekerette Emmanuel Udoh (7326194)

Subjects: